WO2004045555A3 - Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 - Google Patents

Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 Download PDF

Info

Publication number
WO2004045555A3
WO2004045555A3 PCT/US2003/037065 US0337065W WO2004045555A3 WO 2004045555 A3 WO2004045555 A3 WO 2004045555A3 US 0337065 W US0337065 W US 0337065W WO 2004045555 A3 WO2004045555 A3 WO 2004045555A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
fgf
growth factor
fibroblast growth
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/037065
Other languages
French (fr)
Other versions
WO2004045555A2 (en
Inventor
Ken-Ichi Hanada
James C Yang
Donna Perry-Lalley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to EP03796431A priority Critical patent/EP1562622A2/en
Priority to AU2003298677A priority patent/AU2003298677A1/en
Priority to CA002506684A priority patent/CA2506684A1/en
Publication of WO2004045555A2 publication Critical patent/WO2004045555A2/en
Publication of WO2004045555A3 publication Critical patent/WO2004045555A3/en
Priority to US11/134,703 priority patent/US20060009393A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates to peptides for use in immunotherapy of tumors. The peptides disclosed herein are derived from the amino acid sequence of a renal cell carcinoma-associated antigen, fibroblast growth factor-5 (FGF-5). In one example, the peptide is an HLA-A3 epitope (such as NTYASPRFK). In another example, the peptide is an HLA-A2 epitope (such as MLSVLEIFAV). Methods are provided for using such peptides, and variants or fusions thereof, to stimulate an immune response in a subject. The peptides disclosed herein can be formulated into pharmaceutical composition for administration to a subject.
PCT/US2003/037065 1999-10-02 2003-11-19 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 Ceased WO2004045555A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03796431A EP1562622A2 (en) 2002-11-19 2003-11-19 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2
AU2003298677A AU2003298677A1 (en) 2002-11-19 2003-11-19 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2
CA002506684A CA2506684A1 (en) 2002-11-19 2003-11-19 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2
US11/134,703 US20060009393A1 (en) 1999-10-02 2005-05-19 Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42792002P 2002-11-19 2002-11-19
US60/427,920 2002-11-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/134,703 Continuation-In-Part US20060009393A1 (en) 1999-10-02 2005-05-19 Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)

Publications (2)

Publication Number Publication Date
WO2004045555A2 WO2004045555A2 (en) 2004-06-03
WO2004045555A3 true WO2004045555A3 (en) 2004-08-26

Family

ID=32326614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037065 Ceased WO2004045555A2 (en) 1999-10-02 2003-11-19 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2

Country Status (4)

Country Link
EP (1) EP1562622A2 (en)
AU (1) AU2003298677A1 (en)
CA (1) CA2506684A1 (en)
WO (1) WO2004045555A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025271A2 (en) * 1999-10-02 2001-04-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen
US20020031805A1 (en) * 1999-12-29 2002-03-14 Conklin Darrell C. Novel FGF homolog zFGF10

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025271A2 (en) * 1999-10-02 2001-04-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen
US20020031805A1 (en) * 1999-12-29 2002-03-14 Conklin Darrell C. Novel FGF homolog zFGF10

Also Published As

Publication number Publication date
WO2004045555A2 (en) 2004-06-03
EP1562622A2 (en) 2005-08-17
CA2506684A1 (en) 2004-06-03
AU2003298677A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
US9273148B2 (en) Method for cancer immunotherapy
AU7877900A (en) Method of obtaining cellular immune responses from proteins
RU2011121043A (en) CH3 IgE PEPTIDE VACCINE
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
CA2380947A1 (en) Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
GB9818627D0 (en) Improvements in dva vaccination
MXPA01008966A (en) Nucleic acid respiratory syncytial virus vaccines.
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2003076603A3 (en) Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
WO2002032923A3 (en) Improved formulations using heat shock/stress protein-peptide complexes
CA2492938A1 (en) Cancer vaccines containing epitopes of oncofetal antigen
WO2003088995A3 (en) Mucin fusion polypeptide vaccines, compositions and methods of use thereof
CA2078773A1 (en) Gp75 as a tumor vaccine for melanoma
JP2002534481A5 (en)
ATE282634T1 (en) CHAPERONINE 10
CA2360382A1 (en) Use of antibodies for the vaccination against cancer
CA2337754A1 (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
CA2554195A1 (en) Peptide originating in epidermal growth factor receptor (egfr)
WO2003068815A3 (en) Mhc class ii peptide epitope of 5t4 antigen
CN113906046A (en) Immunogenic peptides with oxidoreductase motifs comprising modified cysteines
WO2004045555A3 (en) Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2
WO2000012122A3 (en) Low-molecular fragments of hyaluronic acid for the preparation of vaccines
EP2193804A3 (en) Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
ATE360642T1 (en) MHC CLASS I PEPTIDE EPITOPES OF HUMAN TUMOR-ASSOCIATED ANTIGEN 5T4

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003298677

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2506684

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11134703

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003796431

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003796431

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11134703

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003796431

Country of ref document: EP